Amgen's earnings call highlights continued strong performance despite the ongoing pandemic.  Management expresses cautious optimism for the remainder of the year, noting a potential headwind from the resurgence of COVID-19 cases.  Positive Phase II data for key drug candidates, like sotorasib, and ongoing progress in the pipeline offer a degree of optimism alongside concerns about the pandemic's potential impact on treatment access and general medical practice.
[1]
